PBYIPuma Biotechnology, Inc.

NERLYNX demand surged 12% year over year as Puma raised full-year guidance.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Moby summary of Puma Biotechnology, Inc.'s Q2 2026 earnings call

Puma Biotechnology (NASDAQ:PBYI) reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $

Puma Biotechnology Inc (PBYI) posts $8.2 million GAAP net income, raises full-year revenue and profit outlook, and advances its alisertib clinical program.

Puma Biotech (PBYI) delivered earnings and revenue surprises of +90.00% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.